CrushSCI.com
114.5Average days
110Median days
32Fastest days
203Longest days
3912025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

167 days

Real-world outcomes of asciminib versus first- and second-generation tyrosine kinase inhibitors as second-line treatment for chronic-phase chronic myeloid leukemia

Authors
Ehab L. Atallah; Islam Sadek; Emily McGovern; Dominick Latremouille-Viau; Carmine Rossi; Remi Bellefleur; Nathan Gobeil; Gabriel Marquez; Annie Guérin; Daisy Yang; David WeiShow moreShow less
Affiliations
Medical College of Wisconsin, Milwaukee, United States; Novartis Pharmaceuticals Corporation, East Hanover, United States; Analysis Group, Inc., Montréal, CanadaShow moreShow less
Source PDF DOI Publisher page
203 days

Intensive induction chemotherapy in adult acute myeloid leukemia: A single centre assessment of complete remission and induction mortality

Authors
Zoha Asghar; Nabiha Saeed; Muhammad Usman ShaikhShow moreShow less
Affiliations
Medical College, Aga Khan University, Stadium Road, Karachi, Pakistan; Department of Oncology, Aga Khan University Hospital, Stadium Road, Karachi, Pakistan; Department of Pathology, Laboratory Medicine and Oncology, Aga Khan University Hospital, Stadium Road, Karachi, PakistanShow moreShow less
Source PDF DOI Publisher page
35 days

Comparison allogeneic hematopoietic stem cell transplantation and chemotherapy for consolidation in acute lymphoblastic leukemia in a Colombian Cohort. A propensity score matching analysis

Authors
Juan F. Combariza-Vallejo; Laura María Díaz-CorreaShow moreShow less
Affiliations
Grupo de investigación INPAC, Colombia; Cancer and Hematology departament, Clinica Colsánitas SA, Clínica Universitaria Colombia, Bogotá, Colombia; Hematology department, Hospital Pablo Tobón Uribe, Medellín, ColombiaShow moreShow less
Source PDF DOI Publisher page
74 days

Age over sibling: Younger unrelated donors provide superior outcomes compared to sibling donors in fully matched HCT in older AML/MDS patients

Authors
Witold Prejzner; Alicja Sadowska-Klasa; Johannes Lakner; Anastazja Szlauer-Stefańska; Anna Łojko-Dankowska; Maciej Majcherek; Ewa Karakulska-Prystupiuk; Patrycja Mensah-Glanowska; Anna Czyż; Christian Junghanss; Jan Maciej ZauchaShow moreShow less
Affiliations
Department of Hematology Transplantology and Cell Therapies, Medical University of Gdansk, Poland; Department of Hematology, Transplantology and Cell Therapies, University Clinical Center Gdańsk, Poland; Department of Internal Medicine — Clinic and Policlinic for Hematology, Hemostaseology, Oncology, Stem Cell Therapy and Palliative Medicine, Rostock University Medical Center, Rostock, Germany; Bone Marrow Transplantation and Oncohematology Department, Maria Sklodowska-Curie National Research Institute of Oncology (branch in Gliwice), Gliwice, Poland; Department of Hematology, Transplantation and Cell Therapy, Poznan University of Medical Sciences, Poland; Department and Clinic of Hematology, Cellular Therapies and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland; Department of Hematology, Transplantation and Internal Medicine, Medical University of Warsaw, Poland; Department of Hematology, Jagiellonian University Collegium Medicum, University Hospital in Cracow, Kraków, PolandShow moreShow less
Source PDF DOI Publisher page
119 days

Outpatient step-up dosing of teclistamab and talquetamab in relapsed or refractory

Authors
Kunal Shah; Paul Forrest; Ananya Garg; Pranav Kolluru; David Kaminetzky; Gareth J. Morgan; Marc Braunstein; Oscar Lahoud; Faith E. DaviesShow moreShow less
Affiliations
NYU Grossman School of Medicine, NYU Langone Health, New York, NY, USA; Center for Blood Cancers, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USAShow moreShow less
Source PDF DOI Publisher page
96 days

Readmission in patients with hematologic malignancies: A systematic review and meta-analysis

Authors
Mingfeng Yang; Ya Li; Hui Ju; Jianhong WangShow moreShow less
Affiliations
Department of Haematology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, 250021, ChinaShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does LEUKEMIA RESEARCH take to review a manuscript?

As of 2026-11-19, CrushSCI has 15 complete review records for LEUKEMIA RESEARCH. The fastest paper went from submission to acceptance in 32 days (Influence of IGF2BP3 on t(4;11) fusion mRNA and protein abundance, received 2026-06-26, accepted 2026-07-28); the slowest took 203 days. The average is 114.5 days and the median is 110 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.